IPO

A routine UK disclosure by an investment giant has pulled back the curtain on a major transatlantic auto merger and the silent influence of institutional capital.

A 44% stock implosion and a class-action lawsuit. How Fiserv's broken promises on innovation triggered a crisis and a warning for the FinTech industry.

A class-action suit claims Primo Brands hid merger problems behind a perfect narrative. This is a deep dive into corporate spin and shareholder risk.

OTC-listed Lelantos Holdings, known for renewables, bets its future on a historic Arizona gold-copper mine. A strategic pivot or a high-stakes gamble?

An Auckland firm is using Meta Smart Glasses for pest inspections, giving clients an unprecedented look inside their walls and setting a new standard for transparency.

Destra's fund is boosting distributions by over 21%. We dissect the proprietary strategy driving this yield and the risks investors must consider.

Klaviyo appoints a veteran scaler as co-CEO in a bold move to let its founder focus solely on AI. Is this the new leadership model for tech dominance?

A new platform called Didit is eliminating the biggest barrier in task management: forcing people to sign up. Can this 'zero friction' model change how we delegate?

A Texas vehicle maker is deploying its Bitcoin into regulated DeFi. Is this a risky gamble or the new blueprint for corporate finance innovation?

A massive silver discovery in Nevada isn't just a win for one company; it's a strategic move to secure America's tech and energy future. Here's why.

Led by a controversial figure, AlphaTON Capital pitches a bold Web3 vision in Abu Dhabi, but its grand ambitions clash with stark financial realities.

Law firm Gunderson Dettmer's major partner expansion signals confidence not in the whole market, but in the AI-driven, high-value core of the venture economy.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Amidst a nuclear renaissance, Global Uranium’s detailed mapping in Wyoming de-risks a key project, setting the stage for a critical 2026 drill program.

JFB Construction's CEO just invested $100k of his own money in company stock. We dive into the projects and market trends fueling this bold move.

Spectral Capital projects massive growth via acquisitions and quantum tech, but its ambitious NASDAQ plan faces significant financial and execution hurdles.

The space tourism pioneer is restructuring its debt, buying precious time for its next-gen fleet but at a steep cost for shareholders and future finances.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.